2026-10-25
Greenwich LifeSciences, clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
NAS100 29,813 +0.55%
S&P 7,744 +0.28%
GOLD $4,039 −0.32%
BTC $80,017 −1.54%
VIX 17.11 +1.18%
latest tape · as of 12:02 UTC
The Screen · Healthcare
Greenwich LifeSciences, Inc.
GLSI · Nasdaq · USD · Market cap $226M
Not yet scored16.03 USD
Price as of 23 Oct 2026Daily close, not a live quoteLast reviewed 6 days ago
Screened 2026-10-23 · the tape above runs as of 12:02 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price16.03 USD at the 23 Oct 2026 close
- Ethical screenNot yet scored
- Last reviewed23 Oct 2026 (6 days ago)
A summary of the dated readings below, not a live quote and not advice.
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 16.03 against the desk's fair-value range, base estimate 32.64, over the last year.
- Trend Distribution
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical screen not yet scored
Price16.03 USD
Fair value32.64
Our investment reviews on this name
2026-10-18Read Distribution15.32+4.6% to today Markup gives way to Distribution after a 12% slide in 7 weeks
2026-08-31Read Markup17.34-7.6% to today Distribution gives way to Markup after a 6% rise in 4 weeks
2026-07-31Read Distribution16.32-1.8% to today ✓Markup gives way to Distribution after a 27% slide in 4 weeks
2026-07-02Read Markup22.25-28.0% to today First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
The full research record, in depth, below
This name holds its distribution label.
Greenwich LifeSciences, Inc. holds its Distribution at $16.03. Consolidating, no directional conviction, held for 101 days.
| Phase | Distribution · caution |
| Quantitative state | Consolidating, no directional conviction, held for 101 days |
| Price at the screen | $16.03 |
| Valuation | N/A trailing · -18.78 forward price to earnings |
| Values screen | Not scored |
| Beta | 1.46 |
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 0.00% | Below 33% | Interest-bearing debt is just 0.0% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 0.98% | Below 33% | Cash held in interest-bearing accounts and securities is 1.0% of assets, under the one-third limit. | Pass |
| Receivables | 0.00% | Below 49% | Money owed to the company is 0.0% of assets, under the 49% limit. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadThe Read, in Plain English
Greenwich LifeSciences, clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
2026-09-24
Clears
Greenwich LifeSciences, clears all five screens. Its business is in a permissible area, its debt is near-nil, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
What the Numbers Say It Is WorthThe Fair Value Range
Fair value range in USD, drawn from the 2026-10-23 screen. The gold marker is the market price at the same screen. A 75.6% margin of safety to the base estimate.
Third-party analyst targets: 2 covering, consensus None. The average target sits +256% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-23 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words| Forward P/E | -18.8x |
| EPS, trailing | -1.53 |
| EPS, forward | -0.82 |
| Profit margin | 0.0%currently unprofitable |
| Return on equity | -986.3%not currently earning a positive return on equity |
| FCF yield | -1.48% |
| Current ratio | 1.54healthy short-term liquidity |
| Beta | 1.46moves a little more than the market |
| Short interest, float | 0.21% |
| 52-week range | 7.78 - 34.10 |
| Market cap | $226M |
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeGLSI trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
2026-10-18
Distribution · changed $15.32
-15.4% Entry 7
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 15.4% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 51% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 130%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (2 analysts) rates it none, with a mean price target of $48.
2026-10-02
Markup $18.10
+4.4% Entry 6
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 4.4% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 51% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 130%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (2 analysts) rates it none, with a mean price target of $48.
2026-08-31
Markup · changed $17.34
+6.3% Entry 5
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 6.2% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 51% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 130%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (2 analysts) rates it none, with a mean price target of $48.
2026-07-31
Distribution · changed $16.32
-26.7% Entry 4
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 26.7% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 51% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 130%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (2 analysts) rates it none, with a mean price target of $48.
2026-07-18
Markup $22.25
+0.0% Entry 3
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 51% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 130%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (2 analysts) rates it none, with a mean price target of $48.
2026-07-03
Markup $22.25
+0.0% Entry 2
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02
Markup $22.25
Entry 1
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- 3 Clinical-Stage Cancer Stocks With Pristine Balance Sheets Simply Wall St. · 16 Sep 2026
- 3 Clinical-Stage Cancer Stocks With Pristine Balance Sheets Yahoo Finance · 16 Sep 2026
- Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027 Yahoo Finance · 10 Aug 2026
- Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom Yahoo Finance · 22 Jul 2026
- Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01 Yahoo Finance · 20 Jul 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
KROSKeros Therapeutics, Inc.
SLGLSol-Gel Technologies Ltd.
SYSo-Young International Inc.
ACIUAC Immune SA
SMTISanara MedTech Inc
AVXLAnavex Life Sciences Corp.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-13 | PATEL SNEHAL | Chief Executive Officer | 1,800 | $53,694 | |
| 2026-01-12 | PATEL SNEHAL | Chief Executive Officer | 2,900 | $79,866 | |
| 2025-12-31 | PATEL SNEHAL | Chief Executive Officer | 4,300 | $91,848 | |
| 2025-12-30 | PATEL SNEHAL | Chief Executive Officer | 2,900 | $63,017 | |
| 2025-12-18 | PATEL SNEHAL | Chief Executive Officer | 4,100 | $51,742 | |
| 2025-11-25 | PATEL SNEHAL | Chief Executive Officer | 4,600 | $38,502 | |
| 2025-11-07 | PATEL SNEHAL | Chief Executive Officer | 10,600 | $89,358 | |
| 2025-10-31 | PATEL SNEHAL | Chief Executive Officer | 2,300 | $21,298 | |
| 2025-04-25 | PATEL SNEHAL | Chief Executive Officer | 3,600 | $35,568 | |
| 2025-04-17 | PATEL SNEHAL | Chief Executive Officer | 5,400 | $48,492 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $24.13 | -8.1% | · | $919 | -8.1% |
| 2 months | $25.78 | -14.0% | · | $860 | -14.0% |
| 3 months | $26.54 | -16.4% | · | $836 | -16.4% |
| 6 months | $11.27 | +96.8% | · | $1,968 | +96.8% |
| 1 year | $9.64 | +130.1% | · | $2,301 | +130.1% |
| 2 years | $14.81 | +49.8% | · | $1,498 | +49.8% |
| 3 years | $10.90 | +103.5% | · | $2,035 | +103.5% |
| 5 years | $38.96 | -43.1% | · | $569 | -43.1% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever GLSI does next, these words stay.
Membership
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.